This study focuses on patients with relapsed or refractory large b-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment; refractory means the LBCL did not respond to earlier treatment. The purpose of the study is to compare the usual treatment alone to using the drugs tazemetostat or zanubrutinib plus the usual treatment in these patients. The addition of tazemetostat or zanubrutinib to the usual treatment could shrink the cancer or extend the time without cancer symptoms returning. The usual approach for patients who are not in a study is treatment with chemotherapy, CAR T-cell therapy, stem cell transplant, or a combination of these treatments. To determine treatment effectiveness, researchers will evaluate whether the drugs increase the amount of time before the cancer gets worse by 6 months or more. The study drugs (tafasitamab, lenalidomide, tazemetostat, and zanubrutinib) are approved by the U.S. Food and Drug Administration (FDA) for use in people with lymphoma.
What is the full name of this clinical trial?
S2207 Randomized Phase II Study of the Addition of Tazemetostat or Zanubrutinib to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma